Node-negative breast carcinoma treated without adjuvant systemic therapy

Area of Science:

• Oncology
• Breast Cancer Research
• Clinical Trials

Background:

• Adjuvant systemic therapy is standard for node-negative invasive breast cancer.
• Historical treatment approaches without adjuvant therapy provide valuable insights into disease progression and prognosis.

Purpose of the Study:

• To evaluate the long-term outcomes of node-negative invasive breast cancer patients treated without adjuvant systemic therapy.
• To identify significant prognostic indicators for survival and relapse in this patient cohort.

Main Methods:

• Prospective study of 167 consecutive patients with node-negative invasive breast cancer.
• Treatment administered without adjuvant systemic therapy between 1974 and 1984.
• Median follow-up of 84 months; analysis of overall survival, adjusted survival, and relapse-free survival.

Main Results:

• Five-year overall survival was 81% (66% at 10 years); adjusted survival rates were 91% (83% at 10 years).
• Relapse-free survival rates were 74% at 5 years and 61% at 10 years.
• Tumor size was the only independently significant prognostic factor by multivariate analysis (P < .0125); patient age influenced mortality without recurrence.

Conclusions:

• Tumor size is a critical independent predictor of outcomes in node-negative invasive breast cancer.
• Adjuvant systemic therapy decisions should consider patient age, particularly for those aged 70 and older.
• This historical data highlights the importance of tumor characteristics in predicting breast cancer prognosis.